Literature DB >> 10725288

Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks.

S Mittal1, S Ayati, K M Stein, D Schwartzman, D Cavlovich, P J Tchou, S M Markowitz, D J Slotwiner, M A Scheiner, B B Lerman.   

Abstract

BACKGROUND: Clinical studies have shown that biphasic shocks are more effective than monophasic shocks for ventricular defibrillation. The purpose of this study was to compare the efficacy of a rectilinear biphasic waveform with a standard damped sine wave monophasic waveform for the transthoracic cardioversion of atrial fibrillation. METHODS AND
RESULTS: In this prospective, randomized, multicenter trial, patients undergoing transthoracic cardioversion of atrial fibrillation were randomized to receive either damped sine wave monophasic or rectilinear biphasic shocks. Patients randomized to the monophasic protocol (n=77) received sequential shocks of 100, 200, 300, and 360 J. Patients randomized to the biphasic protocol (n=88) received sequential shocks of 70, 120, 150, and 170 J. First-shock efficacy with the 70-J biphasic waveform (60 of 88 patients, 68%) was significantly greater than that with the 100-J monophasic waveform (16 of 77 patients, 21%, P<0.0001), and it was achieved with 50% less delivered current (11+/-1 versus 22+/-4 A, P<0.0001). Similarly, the cumulative efficacy with the biphasic waveform (83 of 88 patients, 94%) was significantly greater than that with the monophasic waveform (61 of 77 patients, 79%; P=0.005). The following 3 variables were independently associated with successful cardioversion: use of a biphasic waveform (relative risk, 4.2; 95% confidence intervals, 1.3 to 13.9; P=0.02), transthoracic impedance (relative risk, 0.64 per 10-Omega increase in impedance; 95% confidence intervals, 0.46 to 0.90; P=0.005), and duration of atrial fibrillation (relative risk, 0.97 per 30 days of atrial fibrillation; 95% confidence intervals, 0.96 to 0.99; P=0.02).
CONCLUSIONS: For transthoracic cardioversion of atrial fibrillation, rectilinear biphasic shocks have greater efficacy (and require less energy) than damped sine wave monophasic shocks.

Entities:  

Mesh:

Year:  2000        PMID: 10725288     DOI: 10.1161/01.cir.101.11.1282

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  39 in total

1.  Transvenous low energy internal cardioversion for atrial fibrillation refractory to external cardioversion: do non-obese patients benefit?

Authors:  D Pavin; H Legrand; C Leclercq; C Crocq; P Mabo; J C Daubert
Journal:  Heart       Date:  2004-03       Impact factor: 5.994

Review 2.  Theory and practice of defibrillation: (1) Atrial fibrillation and DC conversion.

Authors:  A A J Adgey; S J Walsh
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

Review 3.  [Electrical and pharmacological strategies for early cardioversion of atrial fibrillation].

Authors:  M Linhart; T Lewalter
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

4.  [Outcome parameters for AF trials--executive summary of an AFNET-EHRA consensus conference].

Authors:  P Kirchhof; A Goette; G Hindricks; S Hohnloser; K-H Kuck; T Meinertz; U Ravens; G Steinbeck; G Breithardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-12

5.  Cardioversion: past, present, and future.

Authors:  Ivan Cakulev; Igor R Efimov; Albert L Waldo
Journal:  Circulation       Date:  2009-10-20       Impact factor: 29.690

6.  Cardiotrophin-1: A new predictor of atrial fibrillation relapses after successful cardioversion.

Authors:  Ibrahim Altun; Burak Pamukcu; Cenk Eray Yildiz; Selda Can Arkaya; Goksel Guz; Akar Yilmaz; Ahmet Kaya Bilge; Umit Mutlu Turkoglu; Kamil Adalet
Journal:  Bosn J Basic Med Sci       Date:  2015-07-23       Impact factor: 3.363

7.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

Review 8.  Atrial fibrillation: review of current treatment strategies.

Authors:  Joshua Xu; Jessica G Y Luc; Kevin Phan
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

9.  Higher energy monophasic DC cardioversion for persistent atrial fibrillation: is it time to start at 360 joules?

Authors:  C Boos; M D Thomas; A Jones; E Clarke; G Wilbourne; R S More
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

Review 10.  [Amiodaron for treatment of perioperative cardiac arrythmia: a broad spectrum antiarrythmetic agent?].

Authors:  N Butte; B W Böttiger; P Teschendorf
Journal:  Anaesthesist       Date:  2008-12       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.